Xsolla Partners With Day of the Devs for 2025 to Support New Game Development and Launches at Key Events
13.2.2025 10:00:00 CET | Business Wire | Press release
Day Of The Devs Powered By Xsolla Will Celebrate Creativity And Bring Opportunities Together For Game Developers Of All Genres, Backgrounds, And Locations
Xsolla, a leading global video game commerce company, announces its 2025 flagship sponsorship for Day of the Devs, a non-profit organization celebrating video games' creativity, diversity, and magic. This announcement underscores Xsolla's commitment to empowering game developers and bringing together opportunities for creative talent and development worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213515388/en/
(Graphic: Xsolla)
“This partnership and collaboration underscores our ongoing mission to empower developers and make great games more accessible worldwide no matter what size or where they are from,” said Berkley Egenes, Chief Marketing & Growth Officer. “Day of the Devs powered by Xsolla provides an unparalleled platform to support diverse talent and creativity and create a channel to bring opportunities together for developers, and we are proud to be a part of this initiative.”
Day of the Devs, powered by Xsolla, will include incredible events and opportunities for video game developers to showcase their new games and connect with industry leaders to help them build their gaming businesses. Kicking off 2025, Day of the Devs: San Francisco Edition will take place on Sunday, March 16, 2025, at The Midway in San Francisco, bringing thousands of indie fans and developers together to play incredible hand-picked titles. More details on the event can be found on the Eventbrite page here.
Continuing the celebration, Day of the Devs: GDC Edition will feature a selection of titles from the San Francisco Edition at the Moscone Center during the Game Developers Conference (GDC) 2025, running from March 17 to 21 on the 3rd floor of Moscone West. Attendees can explore these unreleased games during regular hours, while the public, 18 and older, can experience them during GDC Nights on Monday and Thursday evenings from 6:30 PM to 10:00 PM PT. Xsolla will also be hosting a lounge on the first floor of Moscone West to support the community and provide an area for developers to collaborate with the Xsolla team.
Day of the Devs, a non-profit organization, has celebrated video games' creativity, diversity, and magic for over 13 years. It has hosted thousands of attendees at physical events, reached millions through virtual showcases, and provided a platform for hundreds of games and developers.
“This event embodies the spirit of creativity and community that defines indie games,” said Greg Rice, Head Curator at Day of the Devs. “Thanks to partners like Xsolla, we can continue to keep these events free and accessible, allowing thousands to connect with the magic of games and the talent behind them.”
Through this sponsorship, Xsolla will engage with hundreds of game developers to support their initiatives and bring opportunities together to solve inherent questions and challenges facing their funding, distribution, and monetization efforts. This flagship sponsorship reinforces Xsolla’s commitment to supporting game developers to provide the same opportunities and connections to any game - regardless of size, location, genre, or platform. For more information, please visit: xsolla.blog/dotdgdc
About Xsolla
Xsolla is a leading global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, Montreal, and cities around the world.
For more information, visit xsolla.com
About Day of the Devs
Day of the Devs is a non-profit with the mission to celebrate the creativity, diversity and magic of video games. Day of the Devs gives a voice to emerging or underrepresented talent with platforms that connect players with developers, and their games. Day of the Devs takes on the form of virtual and physical events – all completely free, with no costs to either developers or attendees. Over the last 13 years, Day of the Devs has shined a spotlight on many hundreds of games, hosted tens of thousands of people at in-person events, and reached out to millions of viewers through virtual showcases.
For more information, visit dayofthedevs.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213515388/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom